Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027

LONDON, April 3, 2017 /PRNewswire/ --

Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn's Disease, Ulcerative Colitis

The global inflammatory bowel diseases (IBD) drug market is estimated at $8.5bn in 2016 and $9.5bn in 2020. Biologic therapies are expected to be the main drivers of growth in the world IBD drug market over the forecast period. In 2016, the biologics submarket generated revenues of $5.8bn, accounting for 68% of the global IBD drug market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 200-page report you will receive 89 tables and 50 figures - all unavailable elsewhere.

The 200-page report provides clear detailed insight into the global inflammatory bowel diseases (IBD) drug market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope
• Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2017-2027

• Submarket forecasts from 2017-2027:
 - Biologics
 - Aminosalicylates
 - Antibiotics
 - Corticosteroids
 - Immunomodulators

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

• Revenue forecast from 2017-2027 for 17 leading products:
 - Humira
 - Remicade
 - Lialda
 - Asacol
 - Pentasa
 - Xifaxan
 - Cimzia
 - Tysabri
 - Simponi
 - Canasa/Salofalk
 - Entyvio
 - Apriso
 - Medrol
 - Neoral
 - Entocort
 - Uceris
 - Azulfidine

• Revenue forecasts from 2017-2027 for 11 countries:
 - US
 - Japan
 - Germany, France, UK, Spain and Italy (EU5)
 - Brazil, Russia, India and China (BRIC)

• Discussions on research and development, including drug candidates in these classes:
 - Interleukin (IL) inhibitors
 - Cell-adhesion molecule (CAM) inhibitors
 - TNF-alpha inhibitors
 - Stem cell therapies
 - JAK inhibitors
 - Toll-like receptor agonists

• Assessment of selected leading companies that hold major market shares in the inflammatory bowel diseases drug industry

• Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors influencing that industry and market (STEP)

Visiongain's study is intended for anyone requiring commercial analyses for the Global Inflammatory Bowel Diseases (IBD) Drug Market. You find data, trends and predictions.

Buy our report today Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn's Disease, Ulcerative Colitis.

To request a report overview of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44-(0)-20-7336-6100

Or click on:  https://www.visiongain.com/Report/1830/Global-Inflammatory-Bowel-Diseases-(IBD)-Drug-Market-Forecast-2017-2027

List of Companies Mentioned in the Report 

4SC

Abbott Laboratories

AbbVie

Ablynx

Actavis

Active Biotech

Ajinomoto

Allergan

Almirall

Amgen

Aptalis Pharmaceuticals

Astellas

AstraZeneca

Athersys

Atlantic Healthcare

Avaxia Biologics

BioLineRx

Biosafe

Boehringer Ingelheim

Calico

Celgene

Celltrion

Centocor Ortho Biotech

Coherus Biosciences

Coronado Biosciences

Cosmo Pharmaceuticals

Dr. Falk Pharma

Eddingpharm

Elan Pharmaceuticals

Epirus Biopharmaceuticals

Ferring

Forest Laboratories

Galapagos

Giaconda

Google

Harbor Biosciences

Hospira

InDex Pharmaceuticals

Infinity Pharmaceuticals

Isis Pharmaceuticals

Janssen Biotech

Johnson & Johnson

LG Sciences

MedImmune

Mochida

Mutare Health

Mylan Pharmaceuticals

Neovacs

Nisshin Kyorin

Nogra Pharma

Novartis

Oncobiologics

Ortho Biotech

Osiris Therapeutics

Otsuka

Ovamed

Palau Pharma

Pendopharm

Perrigo

Pfizer

Pharmascience

Pluristem Therapeutics

Quest Diagnostics

Ranbaxy Laboratories

Receptos

RedHill Biopharma

Reliance Life Sciences

Roche

Salix Pharmaceuticals

Sandoz

Sanofi

Santarus

Sequella

Shire Pharmaceuticals

Sigmoid Pharma

Soligenix

SonarMD

Takeda Pharmaceuticals

Teva Pharmaceutical Industries

TiGenix

Toray Industries

TxCell

UCB

Valeant

Warner Chilcott

Zydus Cadila

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com